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Objectives The aim of this study was to demonstrate that the prevention of early scaffold area shrinkage of the ABSORB
BVS (Rev.1.1, Abbott Vascular, Santa Clara, California) was sustained and not simply delayed by a few months.
Background With improved scaffold design and modified manufacturing process of its polymer, the second iteration of
ABSORB (BVS 1.1) has improved performance to prevent a scaffold area reduction at 6 months.
Methods Fifty-six patients were enrolled and received 57 ABSORB scaffolds. Quantitative coronary angiography, intravas-
cular ultrasound (IVUS), analysis of radiofrequency backscattering, echogenicity and optical coherence tomogra-
phy (OCT) were performed at baseline and at 12-month follow-up.
Results Overall the scaffold area remained unchanged with IVUS as well as with OCT, whereas the radiofrequency
backscattering and the echogenicity of the struts decreased by 16.8% (p  0.001) and 20% (p  0.001),
respectively; more specifically, the strut core area on OCT decreased by 11.4% (p  0.003). Despite the ab-
sence of scaffold area loss, pharmacological vasomotion was restored. On an intention-to-treat basis, the angio-
graphic late lumen loss amounted to 0.27  0.32 mm with an IVUS relative decrease in minimal lumen area of
1.94% (p  0.12), without significant changes in mean lumen area. The OCT at follow-up showed that 96.69%
of the struts were covered and that malapposition, initially observed in 18 scaffolds was only detected at
follow-up in 4 scaffolds. Two patients experienced peri-procedural and iatrogenic myocardial infarction, respec-
tively, whereas 2 underwent repeat intervention, resulting in the major adverse cardiac event rate of 7.1% (4 of 56).
Conclusions The 12-month performance of the second-generation ABSORB bioresorbable everolimus-eluting scaffold justifies
the conduct of a randomized trial against current best standards. (A Clinical Evaluation of the Bioabsorbable
Everolimus Eluting Coronary Stent System [BVS EECSS] in the Treatment of Patients With de Novo Native Coro-
nary Artery Lesions; NCT00856856) (J Am Coll Cardiol 2011;58:1578–88) © 2011 by the American College of
Cardiology Foundation
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October 4, 2011:1578–88 12-Month Outcomes of the Bioresorbable ScaffoldIn 2000, Tamai et al. (1) reported the first coronary clinical
experience with a bioabsorbable polylactide stent. The stent
was mounted on a standard angioplasty balloon and was
both thermal self-expanding and balloon expandable. The
initial self-expansion occurred after the inflation of the delivery
balloon with heated angiographic contrast medium (up to
70°C), whereas the final self-expansion of the stent occurred at
37°C in the 20 to 30 min after the initial stent deployment.
The 6-month follow-up did not reveal any safety concerns, but
the neointimal growth was comparable to that with a bare-
metal stent. The failure of the stent to reach the clinical arena
was primarily related to the use of heat to induce self-
expansion; there were concerns that it could cause necrosis of
the arterial wall leading to excessive intimal hyperplasia or
increased platelet adhesion leading to stent thrombosis.
See page 1589
In 2007, Erbel et al. (2) described their first experiences
with an absorbable metallic stent made of magnesium. The
rate of restenosis was unacceptable at 6 months as well as at
1 year. However, when restenosis was not observed, the
long-term results showed full resorption of the struts and
return of vasomotion in the scaffolded area (3,4). In 2008,
Ormiston et al. (5) published the 6-month results of 30
patients who received an ABSORB everolimus-eluting
bioresorbable scaffold (Abbott Vascular, Santa Clara, Cali-
fornia); the extent of neointima was comparable to that
observed with a metallic everolimus-eluting stent, but in-
travascular ultrasound (IVUS) and optical coherence to-
mography (OCT) clearly documented a loss in scaffold area
that resulted in an angiographic late loss of 0.44 mm.
However, at 2-year follow-up, IVUS and OCT demon-
strated full resorption of the polymeric struts, with return of
vasomotion in the scaffolded area (6). Furthermore, OCT
and IVUS demonstrated 3 intriguing phenomena: 1) late
luminal enlargement; 2) thinning of the vessel wall; and
3) absence of constrictive or expansive remodeling. In 2010,
a second generation of the ABSORB (Abbott Vascular)
everolimus-eluting bioresorbable scaffold was tested. The
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accepted May 31, 2011.design of the platform and a dif-
ferent manufacturing process of
the polymer ensured a longer and
stronger mechanical integrity of
the device that was confirmed at
6-month follow-up by the near
elimination of late scaffold area
loss together with limited signs of
resorption, documented by OCT,
radiofrequency back scattering,
and echogenicity (7). Concomi-
tantly in 2010, the publication of
the 4-year follow-up of a porcine
model shed light on the entire
resorption process of the scaffold (8).
In humans, however, it re-
mained uncertain whether the fa-
vorable result seen at 6 months
would persist or whether a delayed
inflammatory response accompa-
nied by (very) late recoil and neo-
intimal hyperplasia would occur
mid-term at 12 months. There-
fore, 2 cohorts of approximately 50
patients are being alternatively in-
vestigated either at 6 and 24
months or at 12 and 36 months.
The present report concerns the
cohort scheduled to undergo follow-up at 1 year.
Methods
Study population. The ABSORB Cohort B trial (A Clin-
ical Evaluation of the Bioabsorbable Everolimus Eluting
Coronary Stent System [BVS EECSS] in the Treatment of
Patients With de Novo Native Coronary Artery Lesions) is
a multicenter single-arm trial assessing the safety and
performance of the ABSORB BVS (Rev.1.1, Abbott Vas-
cular) in the treatment of patients with a maximum of 2 de
novo native coronary artery lesions with a maximum diam-
eter of 3.0 mm and a length of 14 mm, with a percentage
diameter stenosis 50% and 100%, and a Thrombolysis
n Myocardial Infarction flow grade of 1 (9).
For patients, major exclusion criteria were presenting
ith an acute myocardial infarction (MI), unstable arrhyth-
ias, left ventricular ejection fraction 30%, restenotic
esions, lesions located in the left main coronary artery,
esions involving an epicardial side branch 2 mm in
iameter by visual assessment, and the presence of thrombus
r another clinically significant stenosis in the target vessel.
he ethics committee at each participating institution
pproved the protocol, and each patient gave written in-
ormed consent before inclusion.
In total, 101 patients were enrolled in the ABSORB
Abbreviations
and Acronyms
2D  2-dimensional
3D  3-dimensional
Ach  acetylcholine
CK  creatine kinase
CK-MB  creatine kinase-
myocardial band
DC  dense calcium
ISA  incomplete scaffold
apposition
IVUS  intravascular
ultrasound
MACE  major adverse
cardiac event(s)
MI  myocardial infarction
MLD  minimal lumen
diameter
NC  necrotic core
OCT  optical coherence
tomography
QCA  quantitative
coronary angiography
ULN  upper limit of
normal
VH  virtual histologyohort B trial. The current article reports the 12-month
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12-Month Outcomes of the Bioresorbable Scaffold October 4, 2011:1578–88clinical and imaging results from the second group (B2) of
56 patients who were randomized to invasive imaging at 12
and 36 months. The remaining 45 patients (B1) have been
randomized to 6- and 24-month follow-up.
Study device. The ABSORB BVS (Abbott Vascular) con-
ists of a polymer backbone of Poly-L lactide coated with a
hin layer of a 1:1 mixture of Poly-D, L-lactide polymer and
he anti-proliferative drug everolimus to form an amorphous
rug-eluting coating matrix containing 100 g of everoli-
mus/cm2 of scaffold. The details of the device have been
reviously described (7,10). On the basis of pre-clinical
tudies, the time for complete absorption of the polymer
ackbone in patients is assumed to be approximately 2 years,
hereas the polymer coating is absorbed in a faster time-
rame (8).
tudy procedure. Target lesions were treated with stan-
ard interventional techniques, with mandatory pre-
ilation. Post-dilation with a balloon shorter than the
mplanted stent was allowed at the discretion of the oper-
tor. Bailout stenting with Xience V (Abbott Vascular) for
dge dissection or insufficient coverage of the lesion oc-
urred in 3 patients. A loading dose of 300 mg of clopi-
ogrel was administered before the procedure, followed by
5 mg daily for a minimum of 6 months, whereas aspirin
as continued lifelong according to the guidelines of the
uropean Society of Cardiology/American Heart Associa-
ion/American College of Cardiology.
efinitions. Clinical device success was defined as success-
ul delivery and deployment of the clinical investigation
caffold at the intended target lesion with attainment of a
nal residual stenosis of 50% by quantitative coronary
ngiography (QCA) (by visual estimation, if QCA unavail-
ble). Bail-out stenting was not considered a device failure.
linical procedure success was defined as in the preceding
ext, using any adjunctive device without the occurrence of
schemia-driven major adverse cardiac events (MACE)
uring the hospital stay with a maximum of first 7 days after
ndex procedure. The composite endpoint was cardiac
eath, any MI, and ischemia-driven target lesion revascu-
arization for a QCA diameter stenosis of50% with either
ymptoms or ischemia or diameter stenosis 70% at the
ime of scheduled or unscheduled angiography. For non–
-wave MI, elevation of creatine kinase (CK) levels 2
imes the upper limit of normal (ULN) with elevated
reatine kinase-myocardial band (CK-MB) was required.
ll events were adjudicated by an independent clinical event
ommittee, and all imaging procedures (QCA, IVUS gray-
cale, IVUS-virtual histology (VH), echogenicity, and
CT) were analyzed by an independent core laboratory
Cardialysis B.V., Rotterdam, the Netherlands). Results
ere reported on an intention-to-treat basis; however, the
rotocol predefines a per-treatment analysis that excludes,
or example, bail-out edge stenting and specific treatment
rotocol violations.
ngiographic assessment. In each patient, the treatedegment and the peri-scaffold segments (defined by a lengthf 5 mm proximal and distal to the scaffold edge) were
nalyzed by quantitative coronary angiography (QCA), in
aired matched angiographic views after procedure and at
ollow-up. All patients (n  56, lesions  57) had 12-
onth angiographic follow-up (100%); 1 lesion had no
atched angiographic views at follow-up. The following
CA parameters were computed: minimal lumen diameter
MLD), reference vessel diameter obtained by an interpo-
ated method, late loss, and binary restenosis, ascertained in
caffold, in peri-scaffold segment, and in segment (scaffold 
peri-scaffold segments) (6).
Vasomotion test. At 1 year, vasomotion was studied with
either methylergonovine or acetylcholine (Ach) according to
local practice of vasomotion testing.
Vasomotion was assessed by measuring changes in mean
lumen diameter in the scaffolded segment and in the 5-mm
proximal and 5-mm distal adjacent segments (11). Vaso-
constriction was defined as a 3% change of the mean vessel
diameter between baseline and vasomotor tone, measured
after the infusion of the maximal dose of Ach (106
mmol/l) (11).
IVUS gray-scale analysis. Treated vessels after procedure
and at follow-up were examined with phased array IVUS
catheters (EagleEye, Volcano Corporation, Rancho Cor-
dova, California) with a pullback speed of 0.5 mm/s. The
region of interest beginning 5 mm distal to and extending 5
mm proximal to the treated segment was examined. The
vessel area, mean and minimum scaffold area, mean and
minimum lumen area, as well as intra-scaffold neointimal
area and lumen area stenosis were measured with a
computer-based contour detection program. Incomplete
apposition was defined as 1 or more scaffold struts separated
from the vessel wall, whereas acquired late incomplete
apposition was defined as incomplete apposition at
follow-up that was not present after procedure.
For echogenicity assessment of polymeric struts at base-
line and follow-up, we used a computer-aided grayscale
value analysis program for strut characterization (12,13).
IVUS radiofrequency analysis. Backscattering of radio-
frequency signals provides information on vessel wall
tissue composition (IVUS-VH) (14). Four tissue compo-
nents (necrotic core [NC]: red; dense calcium [DC]:
white; fibrous: green; and fibrofatty: light green) were
identified with autoregressive classification systems and
expressed as percentages (per cross section, NC  DC 
fibrofatty  fibrous  100%) (14,15). On each cross
section, polymeric scaffold struts were detected as areas of
apparent DC and NC with Shin’s methods (16). We used
the change in quantitative analyses of these areas between
implantation and follow-up as a surrogate assessment of
the chemical and structural alteration of the polymeric
struts (5,6,17).
OCT analysis. As an optional investigation, intravascular
OCT imaging with either time domain OCT (M3 system,
LightLab Imaging, Westford, Massachusetts) or frequency
domain OCT (C7XR system, LightLab Imaging) was
1581JACC Vol. 58, No. 15, 2011 Serruys et al.
October 4, 2011:1578–88 12-Month Outcomes of the Bioresorbable Scaffoldperformed at baseline and at follow-up (10,18–20). The
OCT measurements were performed with proprietary soft-
ware for offline analysis (LightLab Imaging). Adjusting for
the pullback speed, the analysis of continuous cross-sections
was performed at each 1-mm longitudinal interval within
the treated segment.
The ABSORB (Abbott Vascular) scaffold presents im-
portant differences from metallic stents when imaged by
OCT. The optically translucent polymeric struts appear as a
black central core framed by light-scattering borders that do
not shadow the vessel wall and allow complete imaging of
the strut thickness and the vessel behind the struts. The
main quantitative measurements (strut core area, strut
area, lumen area, scaffold area, incomplete scaffold appo-
sition [ISA] area, and neointimal area) require different
analysis rules than for metallic stents (7). Qualitatively,
the diagnosis of late structural strut discontinuity due to
bioresorption can be established: 1) if 2 struts overhang
each other in the same angular sector of the lumen
perimeter, with or without malapposition, covered or
uncovered; or 2) if there is an isolated, covered or
uncovered, strut(s) located more or less at the center of
the vessel without obvious connection with other sur-
rounding struts in 2-dimensional (2D) OCT. Three-
dimensional (3D) OCT analysis might be helpful in
imaging the 3D connection of this apparently isolated
strut with the global structure of the scaffold (7).
The thickness of coverage was measured for every strut
between the abluminal side of the strut core and the lumen.
Because the strut thickness is 150 m, the strut was
considered as covered whenever the thickness of the cover-
age was above this threshold value (7). More detailed
information on the OCT methodology for the tissue cov-
erage assessment is available in the Online Appendix.
Statistical analysis. This was a feasibility study designed to
provide preliminary information on the performance im-
provements of the ABSORB (BVS 1.1, Abbott Vascular)
and to generate hypotheses for future pivotal randomized
studies. The sample size was not defined on the basis of an
endpoint hypothesis but rather to provide information on
device performance. The sample size requirement was
determined by assessing the minimal number of patients
required to provide reliable comparison with the first
ABSORB Cohort A clinical trial (n  30) and the metallic
everolimus eluting stent of the SPIRIT FIRST trial (A
Clinical Evaluation of the Abbott XIENCE V Everolimus
Eluting Coronary Stent System in the Treatment of Pa-
tients With de Novo Native Coronary Artery Lesions) (21).
For binary variables, percentages were calculated.
Kolmogorov-Smirnov distribution was used to test normal-
ity of distribution. Values with normal distribution are
expressed as mean  SD, whereas the others are presented
as median with interquartile range. Paired comparisons
between post-procedure and follow-up were done by a
Wilcoxon signed rank test for continuous variables and with
McNemar’s test for binary variables. Survival curves with allavailable follow-up data were constructed for time-to-event
variables with Kaplan-Meier estimates. Data on patients
who were lost to follow-up were censored at the time of the
last contact (Online Appendix). Because no formal hypoth-
esis testing was planned for assessing the success of the
study, no statistical adjustment was applied. The p values
presented in this paper are exploratory analyses only and
therefore should be interpreted cautiously.
Results
Fifty-six patients were enrolled, and the ABSORB (Abbott
Vascular) investigational device (n  57) was successfully
implanted in all patients (Table 1). Bailout stents (Xience V,
Abbott Vascular) were implanted in 3 lesions.
There were no deaths, either peri-procedurally or at 12
months. Two patients sustained an MI. The first was peri-
procedural: a dissection visible on angiography occurred after
pre-dilation, which was covered by the ABSORB (Abbott
Vascular) implantation. Thrombolysis In Myocardial Infarc-
tion grade 3 flow was restored, despite the presence of a
persisting angiographic dissection distal to the ABSORB
(Abbott Vascular) scaffold. On day 1 after the procedure,
the patient experienced further pain. The electrocardiogram
was unremarkable. Troponin peaked to 0.81 g/l (ULN
0.03 g/l), CK value was 667 U/l (ULN 150 U/l),
and CK-MB value was 97.2 ng/ml (ULN 4 ng/ml).
Baseline CharacteristicsTable 1 Baseline Characteristics
Intention-to-Treat
Populations
(56 Patients, 57 Lesions)
Age, yrs 60 8
Male 40 (71)
Current smokers 12 (21)
Diabetes 11 (20)
Hypertension requiring medication 35 (64)
Hyperlipidemia requiring medication 37 (66)
Prior target vessel intervention 2 (4)
Prior myocardial infarction 9 (16)
Target vessel
Left anterior descending 27 (47)
Left circumflex 12 (21)
Right coronary artery 18 (32)
AHA/ACC lesion classification
A 0 (0)
B1 35 (63)
B2 18 (32)
C 3 (5)
Mean reference vessel diameter, mm 2.58 0.29
Minimum lumen diameter, mm 1.06 0.23
Diameter stenosis, % 59 9
Lesion length, mm 9.7 3.4
Values are mean  SD or n (%).
AHA/ACC  American Heart Association/American College of Cardiology.The symptoms of the patient resolved with medical
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12-Month Outcomes of the Bioresorbable Scaffold October 4, 2011:1578–88therapy, and at follow-up the vessel was widely patent
(late loss: 0.19 mm).
The second patient initially experienced angina (Cana-
dian Cardiovascular Society Angina Classification class III)
on day 18 after the procedure, but a stress test revealed no
ischemia. On day 43, the patient experienced chest pain
during the pre-planned diagnostic angiography, which did
not disclose any angiographic restenosis; without anticoag-
ulation adjustment, the diagnostic procedure was unduly
prolonged by IVUS and OCT examinations. After a failed
attempt at imaging the vessel with OCT, angiography
showed the presence of thrombus surrounding the OCT
catheter in the proximal, mid, and distal vessel. This
intravascular thrombus was treated with the use of an
aspiration extraction device and by multiple doses of intra-
venous heparin given to ensure appropriate anticoagulation.
The intra-scaffold thrombosis and ensuing non–Q-wave MI
(CK 600 U/l [ULN 170 U/l], CK-MB value 72 U/l
[ULN 30 U/l]) were both adjudicated as iatrogenic by the
linical event committee. Nevertheless, the non–Q-wave
I was retained in the MACE count. At follow-up, the
essel was widely patent (late loss: 0.08 mm).
There were 2 ischemia-driven target lesion revasculariza-
ions. In the first patient, an ABSORB BVS (Abbott
ascular) was successfully implanted in a left anterior
escending coronary artery with a dynamic stenosis due to a
yocardial bridge. Core laboratory pre-procedural QCA
emonstrated a systolic diameter stenosis of 84% and a
iastolic diameter stenosis of 26% (Online Fig. 1). Two
onths later, the patient presented with recurrent angina
Canadian Cardiovascular Society class II). Repeat QCA at
months by the core laboratory demonstrated a diameter
tenosis of 85% in systole and a diameter stenosis of 40% in
iastole, which prompted the implantation of a 3.5-mm
ience V (Abbott Vascular) metallic drug-eluting stent. In
Paired QCA AnalysisTable 2 Paired QCA Analysis
Proximal
Reference vessel diameter, mm
Post-procedure 2.77 (2.64 to 2.89)
At 12 months 2.63 0.32
p value between post-procedure and follow-up 0.001
Minimal lumen diameter, mm
Post-procedure 2.43 0.37
At 12 months 2.30 0.36
p value between post-procedure and follow-up 0.003
Acute gain, mm
Late loss, mm 0.12 0.29
Diameter stenosis, %
Post-procedure 13 9
At 12 months 11 (8 to 19)
p value between post-procedure and follow-up 0.75
N  56. Values are mean  SD or median (interquartile range).
QCA  quantitative coronary angiography.he second patient with severe exertional angina, repeatangiography at 12 months revealed a left anterior descend-
ing coronary artery restenosis in the middle of the scaffolded
segment. The IVUS-VH demonstrated intra-scaffold neo-
intimal fibrous tissue. No plausible pre-, post-, or peri-
procedural explanation to the ABSORB BVS (Abbott
Vascular) failure could be put forward. Thus, the hierarchi-
cal MACE rate at 1 year was 7.1% (4 of 56).
Angiographic results. Table 2 summarizes the results of
QCA data at baseline and at follow-up. A typical example
of baseline and follow-up angiography is shown in Figure 1.
At follow-up the intrascaffold MLD decreased from 2.27
.24 mm to 2.00  0.32 mm (p  0.001) with a late loss of
0.27  0.32 mm. There were small but significant changes
in MLD at the proximal (0.12 mm) and distal edges (0.07
mm) of the scaffold. Figure 2 shows the cumulative frequency
distribution curve of the data. The in-scaffold and in-segment
binary restenosis was 2 of 57 (3.5%).
Vasomotion. Thirteen patients received an intravenous
bolus injection of 0.3 mg of methylergonovine, and all of
them except 1 showed some degree of vasoconstriction of
the scaffolded segments, with a significant change in mean
lumen diameter of 0.16 mm (Fig. 3). Of the 24 patients who
had an intracoronary infusion of a maximal dose of Ach
(106 mmol/l), 5 were excluded from analysis because of
navailability of the matched view. Ten patients showed
igns of vasoconstriction in the scaffolded segment, after
dministration of Ach, whereas 8 patients exhibited some
egree of vasodilation. One patient did not show any
asomotion.
ray-scale IVUS, radiofrequency backscattering, and
chogenicity of struts. Over a period of 12 months, the
ean and minimum lumen and scaffold areas remained
nchanged. The amount of neointimal tissue growth was
inimal, with an average area/scaffold of 0.09  0.17 mm2.
Accordingly, the percentage of in-scaffold area obstruction
ention-to-Treat Population (56 Paired Angiographies)
In-Scaffold Distal In-Segment
2.68 0.24 2.56 0.28 2.60 0.28
2.55 0.30 2.38 (2.26 to 2.63) 2.48 0.34
0.001 0.001 0.001
2.27 0.24 2.18 0.37 2.06 0.30
2.06 (1.89 to 2.22) 2.10 0.33 1.96 (1.73 to 2.09)
0.001 0.047 0.001
1.20 0.28
0.22 (0.06–0.41) 0.08 (0.11 to 0.17) 0.16 0.28
15 6 15 10 21 7
20 (15 to 26) 13 10 23 (17 to 27)
0.001 0.10 0.24Intwas minimal (1.43 3.09%). Over time there was a modest
1583JACC Vol. 58, No. 15, 2011 Serruys et al.
October 4, 2011:1578–88 12-Month Outcomes of the Bioresorbable Scaffoldbut significant increase in total plaque area with a concom-
itant increase in vessel area (Table 3). The radiofrequency
backscattering analysis revealed a significant decrease
(17.7%, p  0.001) in pseudo-calcium/calcium, and that
ultrasonic alteration was confirmed by a significant decrease
in echogenicity of the struts (baseline: 23.51  8.57% vs.
12-month: 18.25  7.19%, relative reduction: 19.7%, p 
0.001). The 2 other histological components (fibrotic and
fibrofatty) increased significantly in relative and absolute
terms (Table 3).
OCT analysis. Twenty-one patients with 22 lesions un-
derwent OCT at baseline and at follow-up. An additional 9
patients had only follow-up OCT. The OCT results with
paired analysis (n  22) confirmed the IVUS data: 1) the
mean and minimal scaffold area did not change at follow-
up; and 2) the mean and minimal flow area decreased
significantly by 18.1% and 23.4%, respectively, as a result of
neointimal growth between and over the struts (1.34 0.67
Figure 1 Serial Cineangiograms Before Procedure, After Proced
From right to left in the upper panels, angiogram of a proximal right coronary arte
follow-up (FUP) angiography (before methylergonovine test), 5 min after intravenou
vasomotion test, quantification showed a minimal loss of 0.01 mm at 1-year FU
D  distal segment; LD  lumen diameter; LL  late loss; MLD  minimal lumen
S  scaffolded segment delimited by the presence of metallic radio-opaque markemm2). The lumen area stenosis increased significantly from c20.2% after procedure to 26.9% at 12 months. After
procedure, 18 patients showed ISA, whereas at follow-up
only 4 patients showed ISA. There was no late-acquired
ISA observed. At follow-up ISA area on average for the
patient population with paired analysis was 2.94  1.43
mm2. Among 22 patients with paired OCT at baseline and
at follow-up, 7 patients presented with suspected structural
strut discontinuities, 6 with apposed and covered struts, and
1 with malapposed and uncovered struts. In the case with
malapposed struts suspected to show structural discontinu-
ities in 2D OCT, a 3D OCT reconstruction revealed the
connection of these apparently loose struts (in 2D), with the
surrounding body of the scaffold. As indicated in the
Methods section (and in the Online Appendix), the strut
coverage was analyzed according to 2 different types of
analysis (abluminal black core-lumen, or endoluminal black
core-lumen) and 3 different thresholds of thickness (150
m, or 0 and 30 m). The respective percentages of
and at 12-Month Follow-Up
re procedure, and after procedure. In the lower panels, from left to right, 1-year
tion of methylergonovine and finally 1 min after intracoronary nitrate. Before the
reas restoration of vasomotion is demonstrated during the vasomotion test.
eter; P  proximal segment; QCA  quantitative coronary angiography;ure,
ry befo
s injec
P, whe
diam
rs.overage were 96.9%, 99.8%, and 95.5%.
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The main findings of the current investigation are the
following: 1) despite early signs of bioresorption, the poly-
meric struts are still easily detectable by ultrasound and
OCT; 2) detection of persisting struts allowed accurate
measurement of scaffold areas over time and confirms the
absence of late or very late recoil; 3) the late lumen loss and
the neointimal growth are slightly larger than the loss
measured in the previous cohort that had (B1) 6-month
follow-up but remain comparable to the loss and neointimal
growth observed in a historical series of metallic everolimus-
eluting stents analyzed at the same time point (12 months)
(consequently, the restenosis rate is as low as 3.5%); 4) the
mechanical integrity and radial force of the scaffold must
have substantially subsided, because the scaffolded segments
exhibit clear signs of pharmacologically induced vasomo-
tion; 5) the coverage of the polymeric struts as measured by
OCT does not seem to differ from the observations made
with metallic drug-eluting stents; 6) at 1 year, structural
discontinuity of malapposed struts was detected in a patient
among those having 2D OCT; and 7) the MACE rate at 1
year (7.1%) is comparable to that observed in a historical
series of metallic everolimus-eluting stents.
Early signs of resorption and absence of late recoil.
Three different intravascular imaging techniques used for
monitoring bioresorption concurred in demonstrating that
the process of bioresorption has been initiated and is in
Figure 2 Cumulative Frequency Distribution Curves of Angiogra
Cumulative frequency distribution curves of late loss at 6 and 12 months, BVS 1.1
nary Stent System [BVS EECSS] in the Treatment of Patients With de Novo Native
eluting stent of the SPIRIT FIRST trial (A Clinical Evaluation of the Abbott XIENCE V
Native Coronary Artery Lesions) (22 patients with a serial follow-up at 6 months an
patient with intra-scaffold neointimal hyperplasia documented with intravascular ul
cularization (TLR). Online Figure 1 shows 1 of these cases with myocardial bridge.progress: the measurement by OCT of the black core of thestruts, the radio-frequency backscattering analysis, and the
echogenicity assessment of the strut showed a 11.4%,
16.8%, and 20% relative reduction of their specific signals
(12,22). We are not surprised by differences in signal
reduction between OCT and ultrasound; we have learned
from our clinical experimentation that changes in the OCT
signal do not reflect the molecular dissolution of the
polylactide but rather correspond to the filling by connective
tissue of the void initially occupied by the polymeric struts
(8). In the preclinical porcine model, when analyzing the
explanted treated segments by gel permeation chromatog-
raphy, we have established that molecular weight of the
polylactide is reduced by 40% at 6 months, 70% at 12
months, and approximately 100% at 24 months (8). There-
fore, it is not surprising to see that the radial force of the
scaffold has partially subsided, as demonstrated by the
vasoconstriction and vasodilation induced by vaso-active
drugs. Although the scaffold has lost a great deal of its
mechanical integrity and radial force, it is important to
realize that between baseline and 12 months there has been
no radial displacement of the struts toward the center of the
vessel lumen. In other words, these observations confirm
that the so-called constrictive remodeling is an early and
short-term phenomenon, which is no longer operational 6
months after the scaffold implantation, because the scaffold
at that stage is unable to oppose any mechanical resistance
to the vasoconstrictive action of drugs and thus has lost its
Late Loss: BVS 1.1 (Cohort B) Versus Xience V (Spirit FIRST)
e ABSORB (A Clinical Evaluation of the Bioabsorbable Everolimus Eluting Coro-
ary Artery Lesions) Cohort B1 and B2 trials versus loss of metallic everolimus-
limus Eluting Coronary Stent System in the Treatment of Patients With de Novo
ar). Two patients with myocardial bridge showed high late losses as well as 1
nd-virtual histology. Two patients underwent ischemia-driven target lesion revas-
everolimus-eluting stent.phic
of th
Coron
Evero
d 1 ye
trasou
EES mechanical scaffolding function. These observations sub-
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October 4, 2011:1578–88 12-Month Outcomes of the Bioresorbable Scaffoldstantiate the concept of restenosis as a time-limited process
and thereby validate the principle of a transient need for a
scaffold. Previous published reports have already demon-
Methergin (n=13) 
2.63±0.19 2.47±0.21 2.67±0.20 
P<0.001 p=0.001 
1.8
2
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3.2
Pre Met Nitro 
Figure 3 Vasomotion Test Results at 12 Months
Individual changes in mean lumen diameter of the scaffolded segment during met
and intracoronary nitrate (Nitro). Patients with vasodilation after acetylcholine are
IVUS ResultsTable 3 IVUS Results
Post-PCI
IVUS grayscale, paired intent-to-treat (n  54)
Mean vessel area 13.52 (12.18 to 15.09)
Mean scaffold area 6.29 0.92
Neointimal hyperplasia area —
Mean lumen area 6.31 0.95
Minimum lumen area 5.11 0.96
ISA area* 1.86 1.33
Patients with ISA 5 (9%)
Plaque area 7.23 (6.33 to 8.87)
Lumen area stenosis, % 19.24 6.85
In-scaffold area obstruction, % —
Minimum scaffold area 5.11 0.96
IVUS VH, paired intent-to-treat (n  48)
Fibrous tissue area 1.4 (0.8 to 1.9)
Fibrous tissue area, % 32.1 (25.7 to 38.8)
Fibrofatty tissue area 0.1 (0.0 to 0.2)
Fibrofatty tissue area, % 2.5 (1.0 to 4.0)
Dense calcium area 1.32 0.64
Dense calcium area, % 30.17 10.22
Necrotic core area 1.4 (1.0 to 2.0)
Necrotic core area, % 32.76 6.72
Paired intravascular ultrasound (IVUS) measurements/lesion. Values given are millimeters square
onsistently expressed as median with IQR. *Mean incomplete strut apposition (ISA) area was calculated
PCI  percutaneous coronary intervention; VH  virtual histology.strated that the restenotic process involving constrictive
remodeling ceased to be active 4 months after balloon
angioplasty (23–25).
Acetylcholine (n=19) 
Pre Ach Nitro 
2.45±0.26 2.37±0.24 2.44±0.23 
p=0.146 p=0.055 
novine (Met) or acetylcholine (Ach) test,
ed in blue on the line plot.
365 Days
Difference %, Median (IQR),
on the Basis of Individual Data p Value
14.63 3.06 4.82 11.53 0.012
6.33 0.98 0.90 8.58 0.66
.01 (0.00 to 0.10) — —
6.33 1.17 0.52 13.18 0.20
4.98 0.97 1.94 12.58 0.12
4.48 0.74 — —
4 (7%) — NS
8.30 2.35 8.94 15.69 0.001
21.25 7.54 26.09 77.11 0.30
.20 (0.00 to 1.58) — —
5.07 0.92 0.18 11.21 0.38
1.9 (1.2 to 2.8) 36.2 (1.0 to 66.7) 0.001
40.94 9.50 26.6 (0.0 to 46.3) 0.001
0.2 (0.1 to 0.3) 103.5 (9.5 to 303.7) 0.001
4.0 (2.8 to 6.3) 75.0 (7.4 to 292.4) 0.001
1.16 0.50 16.8 (32.1 to 22.3) 0.022
24.37 7.73 17.7 (35.6 to3.2) 0.001
1.4 (1.0 to 1.9) 5.2 (17.4 to 23.1) 0.992
30.26 6.59 2.7 (20.7 to 12.3) 0.054
s otherwise indicated. Values are mean  SD or median (interquartile range [IQR]). Difference is1.8
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possible increase in loss from 0.19  0.18 mm at 6 months
to 0.27 0.32 mm at 12 months in the present series, when
compared with the previous series analyzed at 6 months,
and a parallel increment in neointimal growth as assessed by
OCT from 1.25  0.36 mm2 at 6 months to 1.34  0.67
mm2 at 12 months. These comparisons are only descriptive
nd have no statistical basis, because the observations are
ot serial but only chronologically related. Without formal
tatistical comparison, we have to underline that serial
nalysis of loss in the SPIRIT FIRST trial showed an
ncrease in angiographic late luminal loss from 0.10  0.23
m at 6 months to 0.23  0.29 mm at 12 months (Fig. 2).
imilarly, in the SPIRIT II trial with serial assessment at 6
nd 24 months, the loss increased from 0.17  0.32 mm to
.33  0.37 mm (26).
We also noticed a slight but significant increase in plaque
edia and vessel wall area, with an increase in fibrotic
omponent from 1.4 to 1.9 mm2 and fibro-fatty from 0.1 to
.2 mm2 without increase in necrotic core over a period of
Figure 4 OCT, IVUS Gray-Scale, and IVUS-VH at Baseline and 1
Baseline post-procedure (left top panel) and 1-year (left bottom panel) optical co
sidebranch selected as an anatomical landmark. Post-procedure, light backscatter
appeared covered but are still visible; neointima partially filled gaps between strut
area remains unchanged. Corresponding grayscale and virtual histology (VH) cross
cular ultrasound.12 months. Noteworthy, the preclinical porcine model
treated with ABSORB BVS (Abbott Vascular) exhibits
histologically at 1 year some remnant inflammatory reaction
with granuloma that completely disappeared at 2 years.
Therefore, in our patients we surmise that some late
regression of plaque media is likely to occur at later
follow-up, as previously documented with the first genera-
tion of ABSORB BVS (1.0) (Abbott Vascular) (6).
Vasomotion. Two types of vasomotor drugs have been
optionally used in the present study: 1) methylergonovine,
which is not endothelial dependent and potentiates contrac-
tion of smooth muscle cells by changing the action potential
pattern so that almost all of our patients who submitted to
this test showed some degree of vasoconstriction; and
2) Ach, which lowers the capillary resistance, thereby
increasing flow and shear stress with stimulation of endo-
thelial receptors with release of nitric oxide through endo-
thelial nitric oxide synthesis activation. Anatomic and func-
tional integrity of coalescent endothelial cells is a sine qua
non condition for a vasodilatory reaction. In our series, 8
nths
e tomography (OCT) assessment of corresponding cross-sectional images with a
ut frames, well-apposed to the vessel wall (left lower panel). At 1 year, all struts
t lower panel). Illustrated is reduction in strut core area, whereas the scaffold
ns at follow-up show reduction of the echogenic backscattering. IVUS  intravas-2 Mo
herenc
ing str
s (righ
-sectio
tile ran
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October 4, 2011:1578–88 12-Month Outcomes of the Bioresorbable Scaffoldpatients showed vasodilation of the scaffolded segment, 1
had unchanged luminal dimension, and 10 patients showed
vasoconstriction of the scaffolded segment (Fig. 3). This
suggests that full coverage by endothelial cells and complete
return of functional capacity of these cells is not yet achieved
in the majority of the patients. In the previous series with 2
years of follow-up, 4 of 9 patients undergoing the test
responded by appropriate vasodilation of the scaffolded
segment (6).
OCT findings. In general, the same OCT methodology as
applied in the 6-month cohort was used in the present series
for reasons of comparability. Nonparametric comparison of
the coverage and neointimal hyperplasia between 6 months
and 12 months did not show significant difference. However,
we documented—at variance with the 6-month analysis—a
significant reduction in strut cross-sectional area (black core),
which methodologically makes the coverage and neointimal
assessment more elusive, because the changing boundaries of
the black core is used as fiducial boundaries for scaffold area
and neointimal area assessment (Fig. 4) (7). The progressive
OCT disappearance of the struts will further compound these
assessments at 2 and 3 years (6,8) (Table 4).
The incidence of suspected structural discontinuity of
apposed and covered struts (4 of 31, 13%) or malapposed
and uncovered struts (3 of 31, 10%), as defined in Methods,
might seem worrisome at first sight. The detection of this
phenomenon, frequently not detectable by IVUS, exempli-
fied the exceptional high resolution of OCT (8). Further-
more, the biological fate of the struts is a programmed
biodegradation and loss of mechanical integrity of the
scaffold, considered as 1 of the basic tenets of this new
technology (24,27). Although rare, the presence of malap-
posed and uncovered struts potentially disconnected from
the otherwise embedded scaffold might raise concerns and
justifies further serial analysis of these cohorts at 2 and 3
years. In the ABSORB Cohort A trial, with the first
ABSORB BVS (Abbott Vascular) generation, we retrospectively
Optical Coherence Tomography ResultsTable 4 Optical Coherence Tomography Res
Baseline
Mean scaffold area 7.66 1.10
Minimal scaffold area 6.23 0.89
Mean lumen area 7.69 1.31
Minimal lumen area 6.11 0.96
Mean prolapse area 0.12 (0.07–0.16)
Mean strut core area 0.19 0.03
Neointimal hyperplasia area NA
Mean flow area 7.51 1.31
Minimal flow area 5.95 0.96
Lumen area stenosis, % 20.17 7.09
ISA area (for patients with ISA) 0.16 (0.08–0.49) (18)
n  22 lesions (21 patients). Values given are millimeters squared,
range). Difference is consistently expressed as median with interquar
ISA  incomplete strut apposition.made a similar observation (28). However, imaging follow-up at 2years showed complete incorporation and disappearance of all
struts, including isolated and malapposed struts.
Review of clinical events. At 12 months in this series, we
had 3 clinical events that could have been either antici-
pated or prevented. Two patients with obvious myocar-
dial bridges were included in the trial; 1 underwent repeat
intervention at 12 months, and the other, asymptomatic,
was still under clinical surveillance after his 12-month
angiographic follow-up. Myocardial bridges generate
compressive pressure (up to 300 mm Hg) capable of fully
closing the vessel in systole. This systolic external com-
pression occurs at least 100,000 times/day and, as ex-
pected, a bioresorbable transient scaffold yields to such a
mechanical stress. An increased incidence of in-stent
restenosis, enhanced neointimal hyperplasia, and stent
fracture has also been reported after placement of metallic
drug-eluting stent in myocardial bridges (29). Second,
the case of iatrogenic thrombosis could have been pre-
vented by proper anticoagulation during unduly pro-
longed intravascular investigations.
Future prospect. When the clinical results of the Cohort
B1 and B2 trials are pooled, the hierarchical MACE rate of
the 101 patients at 12 months is 7% (7 of 101), even if we
include the iatrogenic events described in the preceding text.
Without performing a formal comparative analysis with
adjustment, which in this simple population seems to be
superfluous, it seems that the MACE rate at 12 months is
similar to the rate observed in the historical series of the
Xience V (Abbott Vascular) metallic everolimus-eluting
stent (Online Fig. 2). These results constitute the founda-
tion for the upcoming pivotal trial that plans to compare, at
1 year, the ABSORB (Abbott Vascular) bioresorbable
everolimus-eluting scaffold with the metallic stent eluting
the same drug (Xience Prime, Abbott Vascular). Ideally, in
a trial, analysis of endothelial dysfunction by Ach should be
recommended in a large proportion of patients, because the
12-Month
Relative Difference on the
Basis of Individual Data, % p Value
59 1.25 0.66 10.39 0.30
08 1.18 2.05 14.84 0.33
0 (5.32–6.53) 19.81 15.07 0.001
52 1.27 25.41 18.25 0.001
NA — —
16 0.02 11.44 21.21 0.003
34 0.67 — —
8 (5.32–6.53) 18.08 14.93 0.001
51 1.25 23.41 18.79 0.001
86 8.23 52.29 84.54 0.020
94 1.43 (4) — —
therwise indicated. Values are mean  SD or median (interquartile
ge.ults
7.
6.
5.7
4.
0.
1.
5.6
4.
26.
2.
unless otime course of reversal endothelial dysfunction could be
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antiplatelet therapy.
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